First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: A happy union?

被引：8
|
作者：
Thilaganathan, B [1 ]
机构：
[1] Homerton Hosp, Acad Dept Obstet & Gynaecol, London, England
来源：
ULTRASOUND IN OBSTETRICS & GYNECOLOGY | 1999年 / 13卷 / 04期
关键词：
D O I：
10.1046/j.1469-0705.1999.13040229.x
中图分类号：
O42 [声学];
学科分类号：
070206 ; 082403 ;
摘要：
引用
收藏
页码：229 / 230
页数：2
相关论文
共 50 条
  • [31] Nuchal translucency and first trimester biochemical markers for Down syndrome screening: A cost-effectiveness analysis
    Caughey, AB
    Kuppermann, M
    Norton, ME
    Washington, AE
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (05) : 1239 - 1245
  • [32] First-trimester screening for Down syndrome using quadruple maternal biochemical markers
    Caron, Laurence
    Fillion, Alexandre
    Giguere, Yves
    Audibert, Francois
    Forest, Jean-Claude
    Gasse, Cedric
    Girard, Mario
    Laforest, Genevieve
    Guerby, Paul
    Bujold, Emmanuel
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2023, 61 (09) : 1630 - 1635
  • [33] Nuchal translucency measurements for first-trimester screening: The 'Price' of inaccuracy
    Evans, Mark I.
    Van Decruyes, Hilde
    Nicolaides, Kypros H.
    FETAL DIAGNOSIS AND THERAPY, 2007, 22 (06) : 401 - 404
  • [34] If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases
    Marsk, Anna
    Grunewald, Charlotta
    Saltvedt, Sissel
    Valentin, Lil
    Almstrom, Harald
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2006, 85 (05) : 534 - 538
  • [35] The effect of maternal polycystic ovary morphology on first-trimester maternal serum biochemical markers of aneuploidy and fetal nuchal translucency thickness
    Hacivelioglu, S.
    Uysal, A.
    Gungor, A. N. Cakir
    Gencer, M.
    Cakir, D. U.
    Cosar, E.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2015, 42 (01): : 32 - 35
  • [36] First trimester screening for Down's syndrome using maternal serum PAPP-A and free β-hCG in combination with fetal nuchal translucency thickness
    Biagiotti, R
    Brizzi, L
    Periti, E
    d'Agata, A
    Vanzi, E
    Cariati, E
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1998, 105 (08): : 917 - 920
  • [37] Maternal serum invasive trophoblast antigen and first-trimester down syndrome screening
    Palomaki, GE
    Knight, GJ
    Neveux, LM
    Pandian, R
    Haddow, JE
    CLINICAL CHEMISTRY, 2005, 51 (08) : 1499 - 1504
  • [38] ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome
    Laigaard, Jennie
    Spencer, Kevin
    Christiansen, Michael
    Cowans, Nicholas J.
    Larsen, Severin Olesen
    Pedersen, Bent Norgaard
    Wewer, Ulla M.
    PRENATAL DIAGNOSIS, 2006, 26 (10) : 973 - 979
  • [39] First-trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down's syndrome: Implications for first-trimester screening with nuchal translucency and serum free beta hCG
    Spencer, K
    Noble, P
    Snijders, RJM
    Nicolaides, KH
    PRENATAL DIAGNOSIS, 1997, 17 (06) : 525 - 538
  • [40] First-trimester screening for Down's syndrome
    Leporrier, N
    Leymarie, P
    Herrou, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (06): : 620 - 620
12345